Uptravi is a medication developed and manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1]. It is used to treat pulmonary arterial hypertension (PAH) [2].
How does Uptravi work for PAH?
Uptravi, also known by its generic name selexipag, is a prostacyclin receptor (IP receptor) agonist [3]. It works by dilating (widening) blood vessels in the lungs, which reduces blood pressure and eases the workload on the right side of the heart [4].
What is the difference between Uptravi and other PAH treatments?
Uptravi is an oral medication that targets the prostacyclin pathway, offering a distinct mechanism of action compared to some other PAH therapies that may target different pathways or have different administration methods [3][4]. For example, other treatments might include endothelin receptor antagonists or phosphodiesterase-5 inhibitors [5].
When does Uptravi's patent expire?
Information on specific patent expiry dates for Uptravi (selexipag) is typically detailed on specialized patent tracking websites. DrugPatentWatch.com provides a database that can offer insights into patent statuses and expiration timelines for pharmaceuticals [1].
What are the common side effects of Uptravi?
Common side effects reported with Uptravi include headache, diarrhea, nausea, vomiting, jaw pain, muscle pain, and pain in extremity [6].
What are the risks associated with Uptravi treatment?
Potential risks associated with Uptravi include bleeding events, as it can affect platelet aggregation [7]. Patients should discuss their full medical history, including any bleeding disorders or anticoagulant use, with their healthcare provider.
Can Uptravi be used in combination with other PAH medications?
Uptravi can be used alone or in combination with other PAH therapies, such as endothelin receptor antagonists or phosphodiesterase-5 inhibitors, as determined by a healthcare professional [4][5].
What clinical trials have been conducted for Uptravi?
The efficacy and safety of Uptravi were established through clinical trials, including the GRIPHON trial, which demonstrated its ability to reduce the risk of morbidity and mortality in patients with PAH [3].
Who manufactures Uptravi?
Uptravi is manufactured by Janssen Pharmaceuticals, which is part of the Johnson & Johnson family of companies [1].